Published in Cancer Biother Radiopharm on March 06, 2015
Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis. J Natl Cancer Inst (2015) 0.91
Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging (2016) 0.85
Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging (2015) 0.82
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol (2017) 0.75
Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med (2016) 0.75
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol (2014) 3.40
Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol (2013) 1.90
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol (2014) 1.70
The promise of targeted {alpha}-particle therapy. J Nucl Med (2005) 1.43
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2013) 1.20
Bone-seeking radionuclides for therapy. J Nucl Med (2005) 1.12
Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian J Androl (2014) 1.12
Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride. J Nucl Med (2013) 1.10
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 1.10
Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol (2014) 0.90
Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res (2013) 0.89
How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. Can J Urol (2014) 0.86
New agents in the arsenal to fight castrate-resistant prostate cancer. Curr Oncol Rep (2013) 0.84
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist (2014) 0.83
Radium-223 dichloride for the treatment of metastatic prostate cancer. Expert Opin Pharmacother (2014) 0.83
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Med (2014) 0.82
Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int (2012) 0.80